Atara biotherapeutics announces first patient enrolled in randomized placebo-controlled study of allogeneic t-cell therapy ata188 in progressive forms of multiple sclerosis

Atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy leveraging its novel allogeneic ebv t-cell platform to develop treatment
ATRA Ratings Summary
ATRA Quant Ranking